Cadila Healthcare hits new high on USFDA approval for new drug

The stock rallied 10% to Rs 539, also its new high on BSE in intra-day trade

Cadila Healthcare rallied 10% to Rs 539, also its new high on BSE in intra-day trade, after Zydus Cadila said the US Food and Drug Administration (USFDA) has given the final approval to market the company’s Mesalamine Delayed-Release tablets USP, 1.2 g in the US market.

Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda (Mesalamine).

“Lialda is indicated for the treatment of mild to moderate ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects approximately 700,000 people in the United States,” the company said